Hyperglycemia

The grounding supports diabetes-related metabolic dysregulation as a major context for hyperglycemia, particularly insulin resistance and impaired insulin action in type 2 diabetes. It also notes chemically induced hyperglycemia as a literature topic, but does not provide specific causal agents.

Chronic elevations in glucose are associated with increased production of reactive oxygen species and reactive nitrogen species, leading to oxidative stress. These processes can damage DNA, proteins, and lipids and activate stress-sensitive signaling pathways, contributing to insulin resistance, beta-cell dysfunction, and tissue injury.

Obesity is identified as a major susceptibility factor in the type 2 diabetes literature linked to hyperglycemia. The grounding also supports insulin resistance, dyslipidemia, hyperinsulinemia, and low-level inflammation as associated factors in the development and progression of hyperglycemic states.

Management is described at the level of lifestyle measures and glucose-lowering drug classes for type 2 diabetes-associated hyperglycemia. The consensus reports emphasize lifestyle management, diabetes self-management education and support, weight management, and medications including insulin, SGLT2 inhibitors, and GLP-1 receptor agonists; earlier guidance also discusses broader use of oral and injectable antihyperglycemic therapies.